“…The region of the viral genome that codes for NS5B has been described as an important target in therapy with IFN and rBV (Kukolj et al 2005, Lu et al 2007, Lutchman et al 2007). The mechanisms that lead to viral resistance after IFN/ rBV treatment is still a matter of debate (Horiike et al 1999, Hadziyannis et al 2004, Kanda et al 2004, Hamano et al 2005, Hofmann et al 2007, Chung et al 2008, Kuntzen et al 2008, Kwong et al 2008, Nakamura et al 2008, Cannon et al 2009, Gaudieri et al 2009, rydberg et al 2009).…”